2018 ASCO Annual Meeting!
Session: Health Services Research, Clinical Informatics, and Quality of Care
Type: Poster Session
Time: Saturday June 2, 1:15 PM to 4:45 PM
Location: Hall A
A randomized, controlled trial to assess a multi-level intervention to improve adherence to oral cancer medications.
Disparities/Access to Care
Health Services Research, Clinical Informatics, and Quality of Care
2018 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #446a)
J Clin Oncol 36, 2018 (suppl; abstr TPS6621)
Author(s): Rashmika Potdar, Sneha Karki, Claudia M. Dourado, Kamran Mohiuddin, Djeneba Audrey Djibo, John Charles Leighton, Jean G Ford; Einstein Medical Center Philadelphia, Newtown Square, PA; Einstein Medical Center Philadelphia, Philadelphia, PA; Albert Eisntein Medical Center, Blue Bell, PA; Einstein Medical Center, Philadelphia, PA; Albert Einstein Heathcare Network, Philadelphia, PA
Background: Cancer treatment with oral cancer medication is complex. Cancer patients require substantial skills to adhere to- and achieve the goals of therapy. Medication adherence among cancer patients is increasingly important, as treatment with oral medications is increasingly prevalent. The rates of adherence to oral therapy vary widely by population, cancer type, and level of education. To date, however, there is no clear evidence on the effect of improvements in health literacy on patients’ adherence to oral cancer medications. We hypothesize that compared to usual care, the addition of a multilevel intervention will result in greater adherence to oral cancer medications. Methods: In a single-center, patients are randomized 1:1 to receive usual care, including clinical care plus education by a registered nurse (Arm 1), or the addition of a multilevel intervention (Arm 2). The multilevel intervention includes a brief web-based educational video on cancer and oral cancer drugs, periodic reinforcement of educational messages with videos, brief phone calls 24 hours and 2 weeks after each encounter, and offer of facilitative services, if needed. Health literacy is recorded at baseline, using REALM R. Adult cancer patients on any oral cancer medication are eligible to participate in the study. Exclusion criteria include ECOG ≥3, concurrent chemo-radiation, hormonal therapy, non-adherence (defined as history of missing 2 or more Oncology clinic appointments), pregnancy, residence in a nursing home, dementia, or lacking decisional capacity. The primary outcome of interest is medication adherence, indicated by the proportion of expected refills completed for oral cancer medications during the follow up period. Secondary outcomes include adherence to follow up visits, adherence to other prescribed medications, healthcare utilization, and other healthcare outcomes. With a one-sided alpha = 0.05, the target sample size of 110 patients, would yield 90% power to test the primary hypothesis. To date, we have randomized 19 participants, and enrollment proceeds as planned. Clinical trial information: NCT03245411